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Abstract
High levels of serum cholesterol and disruptions of the blood brain barrier (BBB) have all been
implicated as underlying mechanisms in the pathogenesis of Alzheimer's disease. Results from
studies conducted in animals and humans suggest that caffeine might be protective against
Alzheimer's disease but by poorly understood mechanisms. Using rabbits fed a cholesterol-
enriched diet, we tested our hypothesis that chronic ingestion of caffeine protects against high
cholesterol diet-induced disruptions of the BBB. New Zealand rabbits were fed a 2% cholesterol-
enriched diet, and 3 mg caffeine was administered daily in drinking water for 12 weeks. Total
cholesterol and caffeine concentrations from blood were measured. Olfactory bulbs (and for some
studies hippocampus and cerebral cortex as well) were evaluated for BBB leakage, BBB tight
junction protein expression levels, activation of astrocytes, and microglia density using histological,
immunostaining and immunoblotting techniques. We found that caffeine blocked high cholesterol
diet-induced increases in extravasation of IgG and fibrinogen, increases in leakage of Evan's blue
dye, decreases in levels of the tight junction proteins occludin and ZO-1, increases in astrocytes
activation and microglia density where IgG extravasation was present. Chronic ingestion of caffeine
protects against high cholesterol diet-induced increases in disruptions of the BBB, and caffeine and
drugs similar to caffeine might be useful in the treatment of Alzheimer's disease.
Introduction
The blood-brain barrier (BBB), a physical and metabolic
barrier between the central nervous system and the sys-
temic circulation, helps regulate and protect the microen-
vironment of brain [1,2]. BBB breakdown occurs in a
variety of neurological disorders including brain trauma
[3], stroke [4], multiple sclerosis [5], HIV-1 dementia [6],
Alzheimer's disease [7] and Parkinson's disease [8].
Changes in cholesterol homeostasis and high dietary cho-
lesterol have been implicated in some of these neurologi-
cal disorders (especially stroke and Alzheimer's disease)
and have been shown to increase BBB leakage [9,10].
Because BBB functions to protect the central nervous sys-
tem and disruption of BBB precedes neurological disor-
ders such as stroke [11] and Alzheimer's disease [12],
increased BBB leakage resulting from cholesterol-enriched
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diets might underly, at least in part, these neurological
disorders.
Recent epidemiological and experimental studies indicate
that caffeine, when administered chronically, has benefi-
cial effects against a number of neurovascular disorders
including stroke and Alzheimer's disease [13-20]. We
[21,22] and others [18] have demonstrated beneficial
effects of caffeine in early onset models of Alzheimer's dis-
ease. Here, we used rabbits fed a cholesterol-enriched diet
as a model for sporadic Alzheimer's disease where prob-
lems with BBB integrity have been noted [9,10]. These
studies were conducted mainly using olfactory bulbs,
however confirmatory studies were conducted with hip-
pocampus and cerebral cortex. Olfactory bulbs are a brain
region with an intact BBB and are a region important for
olfaction. In neurodegenerative diseases generally and
Alzheimer's disease particularly, patients experience olfac-
tory dysfunction [23]. Indeed, olfactory dysfunction has
been suggested to be among the earliest symptoms of
Alzheimer's disease and beta amyloid plaque and tau
pathologies in the olfactory system have been reported in
Alzheimer's disease [24]. Accordingly, olfactory bulbs are
an important region with which to test the hypothesis that
chronic ingestion of caffeine protects against high choles-
terol diet-induced disruptions of the BBB.
Materials and methods
Animals
New Zealand white rabbits (1.5 to 2 years old) weighing
3 to 4 kg were used in the present study. Rabbits were ran-
domly assigned to four groups; normal chow, normal
chow + 3 mg/day caffeine, 2% cholesterol-enriched diet,
2% cholesterol-enriched diet + 3 mg/day caffeine. Caf-
feine was administered daily in 50 ml of drinking water
starting from the beginning of these cholesterol feeding
experiments. To help ensure that the rabbits drank the
water in the absence or presence of caffeine, water was
withheld for the prior 6 h and once the 50 ml were fin-
ished water was provided ad libitum for the remaining ~18
h/day. After 12 weeks of treatment, animals were anesthe-
tized and perfused with PBS. Olfactory bulbs, hippocampi
and cerebral cortices were dissected, frozen on a liquid
nitrogen cooled surface, and stored at -80°C until taken
for experimentation. All experiments were approved by
the Committee for Animal Care and Use at the University
of North Dakota.
Evan's blue leakage assay
Evans blue dye (25 mg/kg) was injected i.p. and 3 h after
injection plasma samples were collected via ear vein. Sub-
sequently, rabbits were anesthetized heavily with keta-
mine/xylazine (50/5 mg/kg), and animals were perfused
with 37°C oxygenated phosphate-buffered saline until
colorless perfusion fluid was obtained from the right
atrium. Following perfusion, brains were obtained
quickly; olfactory bulbs, cerebral cortex and hippocampus
were removed, weighed, and incubated for 72 h with for-
mamide in the dark at room temperature. After incuba-
tion, samples were centrifuged at 10,000 × g for 10
minutes, supernatants were collected, and absorbance was
measured at 620 nm. Evan's blue concentrations were cal-
culated from standard curves. Final values were expressed
as Evan's blue/specimen weight normalized to plasma
Evan's blue concentration.
Immunohistochemistry
Cryostat brain sections (14 µm) were fixed with acetone
and stained for target proteins using antibodies to rabbit
IgG (Jackson ImmunoResearch), fibrinogen (BD
Pharmingen, clone 2C2-G7), CD31 (Abcam, clone JC/
70A), vwf (Abcam, clone F8/86), and GFAP (Sigma, Clone
G-A-5). Microglia were stained with biotin-conjugated
Griffonia simplicifolia isolectin B4 (Molecular Probe).
Fluorescent labeling with antibodies to ZO-1 (Zymed,
clone ZO1-1A12) and occludin (Zymed, clone OC-3F10)
were used for assessment of tight junction protein expres-
sion. For double immunostaining of IgG extravasation
and the expression of occludin, ZO-1 or GFAP, sections
were first incubated with biotin-conjugated goat anti-rab-
bit IgG and monoclonal antibodies to occludin, ZO-1 or
GFAP, then incubated with Extravidin-TRITC (Sigma) and
FITC-conjugated goat anti-mouse secondary antibodies.
For double immunostaining of IgG extravasation and
microglia, sections were first incubated with goat anti-rab-
bit IgG and biotin-conjugated Griffonia simplicifolia iso-
lectin B4, then incubated with Texas Red-conjugated
donkey anti-goat secondary antibody and Extravidin-
FITC. Sections were examined by conventional (Leica) as
well as confocal (Olympus) microscopy. Images were ana-
lyzed with Image J software.
Immunoblotting
Olfactory bulb lysates containing equal amounts of pro-
tein were resolved with 10% SDS-PAGE and immunoblot-
ted on membranes with antibodies to rabbit IgG,
fibrinogen, GFAP, ZO-1, and occludin. Protein levels of
rabbit IgG and fibrinogen in equal volumes of plasma
were also resolved with SDS-PAGE and immunoblotted
on membranes with antibodies to rabbit IgG and fibrino-
gen.
Cholesterol measurements
Total serum cholesterol and high-density lipoproteins
(HDL) were measured in venous blood collected from
rabbit ear veins. Lipid levels were measured by standard
techniques with an Olympus AU640 clinical analyzer.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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Caffeine measurements
Caffeine concentrations from blood were analyzed with
high-performance liquid chromatography (HPLC). Pro-
teins and lipids were removed with 2% trichloroacetic
acid (TCA). After centrifugation at 12,500 × g for 15 min
at 4°C, supernatants containing caffeine were collected.
TCA in the supernatant was neutralized and separated
with a mixture of tri-n-octylamine/dichloromethane
(225:775). Samples were analyzed with a Supercosil C-
18T column (4.6 × 150 mm, Supelco) using a mobile
phase of 0.05 M KH2PO4 containing 4% acetonitrile at pH
3.8 run isocratically at 1.0 ml/min. Caffeine was detected
with a photo-diode array 168 detector (Beckman Coulter)
set to measure at 273 nm. Levels of caffeine were quanti-
fied by comparing peak heights and areas under the peaks
with those obtained after sample spiking with caffeine
and by comparison with values obtained with external
caffeine standards.
Statistical analyses
All data were expressed as means and SEM. Statistical sig-
nificance for multiple comparisons was determined by
two-way ANOVA and a Bonferroni post-hoc test. p < 0.05
was considered to be statistically significant.
Results
Caffeine blocks high cholesterol diet-induced increases in 
IgG and fibrinogen extravasation
Rabbits fed cholesterol-enriched diets have been used
extensively to model cardiovascular disorders including
atherosclerosis and more recently neurovascular disorders
associated with sporadic Alzheimer's disease [25]. To
investigate the effects of cholesterol-enriched diet and caf-
feine on BBB leakage, we first examined extravasation of
endogenous IgG and fibrinogen. Because IgG and fibrino-
gen are not present normally in brain parenchyma,
increases in the immunoreactivity of IgG and fibrinogen
in brain indicate BBB leakage. Frozen sections of olfactory
bulb were stained for IgG and fibrinogen and we found,
in 2 of 6 rabbits examined from each group and in 6 sec-
tions from each animal, that the immunoreactivity of
both IgG (Fig 1A) and fibrinogen (Fig 2A) was present
perivascularly and that the cholesterol-enriched diet
increased markedly IgG (Fig 1A) and fibrinogen (Fig 2A)
extravasation. Increased extravasation of IgG, as examined
by immunostaining, was present as well in cerebral cortex
and hippocampus (data not shown). High cholesterol
diet-induced increases in extravasation of IgG (Fig 1A)
and fibrinogen (Fig 2A) in olfactory bulb were blocked by
3 mg of caffeine administered daily in drinking water for
12 weeks. In contrast, in olfactory bulb samples from con-
trol rabbits, caffeine alone had no effect on IgG (Fig 1A)
and fibrinogen (Fig 2A) extravasation.
To confirm and extend the qualitative immunohisto-
chemical results, we quantitatively evaluated the integrity
of the BBB by measuring protein levels of IgG and fibrin-
ogen using immunoblotting techniques. Consistent with
our immunohistochemical results, the high cholesterol
diet increased significantly (p < 0.05) protein levels of IgG
(Fig 1B) and fibrinogen (Fig 2B) in olfactory bulb, and
these increases were blocked completely and significantly
(p < 0.05) by caffeine at the dose of 3 mg/day for 12
weeks. In control rabbits, caffeine did not change signifi-
cantly the protein levels of IgG (Fig 1B) and fibrinogen
(Fig 2B). To determine whether accumulation of IgG and
fibrinogen in brain was due to increased levels of plasma
IgG and fibrinogen possibly resulting from peripheral
inflammation, we examined plasma levels of IgG and
fibrinogen with immunoblotting and found that neither
cholesterol-enriched diet nor caffeine changed signifi-
cantly plasma levels of IgG (Fig 1C) and fibrinogen (Fig
2C).
Caffeine blocks high cholesterol diet-induced leakage of 
Evan's blue dye
We next evaluated BBB leakage using a quantitative Evan's
blue dye leakage assay in 2 rabbits from each group and
found that high cholesterol diet significantly increased
leakage of Evan's blue dye in olfactory bulb (Fig 3A), cer-
ebral cortex (Fig 3B) and hippocampus (Fig 3C). Inges-
tion of caffeine at the dose of 3 mg/day for 12 weeks
attenuated high cholesterol diet-induced leakage of Evan's
blue dye in olfactory bulb (Fig 3A), cerebral cortex (Fig
3B), and hippocampus (Fig 3C).
Caffeine blocks high cholesterol diet-induced down-
regulation of tight junction proteins
The restrictive nature of the BBB is due mainly to tight
junctions between adjacent endothelial cells. Stabiliza-
tion of tight junctions involves a complex network of tight
junction proteins such as occludin, claudins and zonula
occludens (ZO) that link transmembrane proteins to the
actin cytoskeleton [26]. Accordingly, we next determined
the effects of cholesterol-enriched diet in the absence and
presence of caffeine on expression levels of these proteins.
Immunohistochemically, we observed, in 2 of 6 rabbits
examined from each group and in 6 sections from each
animal, significantly decreased occludin and ZO-1 immu-
nostaining in olfactory bulb of cholesterol-fed rabbits,
and this effect of cholesterol on these tight junction pro-
teins was blocked by caffeine at the dose of 3 mg/day (Fig
4B, C, E and 4F). Protein levels of occludin and ZO-1, as
determined by immunoblotting, were examined in con-
trol and cholesterol-fed animals. Caffeine blocked high
cholesterol diet-induced decreases in the expression of
occludin (Fig 4D) and ZO-1 (Fig 4G). Similar results were
observed in hippocampus of cholesterol-fed and caffeine-
treated cholesterol-fed rabbits (data not shown). We alsoJournal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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examined the expression of tight junction proteins at the
sites where BBB leakage was apparent using double fluo-
rescent immunostaining. We observed that cholesterol-
enriched diet decreased markedly the density of immuno-
reactive staining for occludin (Fig 5) and ZO-1 (Fig 6) at
the sites where extravasation of IgG was present. These
effects were all blocked by chronic ingestion of caffeine at
the dose of 3 mg/day for 12 weeks.
Caffeine does not affect plasma levels of cholesterol
In 4 rabbits from each group, we measured caffeine (µM)
levels in serum using HPLC. Caffeine levels in rabbits fed
control diet or cholesterol-enriched diet were not detecta-
Caffeine blocks high cholesterol diet-induced extravasation of IgG Figure 1
Caffeine blocks high cholesterol diet-induced extravasation of IgG. (A) Cholesterol-enriched diet increased extrava-
sation of IgG in olfactory bulb and this effect was blocked by caffeine at the dose of 3 mg/day. Caffeine alone had no effect on 
extravasation of IgG in normal rabbit brain. Representative images taken from 2 rabbits in each group with 6 sections from 
each animal are shown. Bar = 50 µm. (B) Cholesterol-enriched diet significantly increased accumulation of IgG in olfactory bulb 
and this effect was blocked by caffeine at the dose of 3 mg/day. (C) Neither cholesterol-enriched diet nor caffeine changed sig-
nificantly plasma levels of IgG. n = 4, *p < 0.05.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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ble. Caffeine levels were 5.3 ± 1.6 in the serum of rabbits
fed control diet plus 3 mg/day caffeine, and were 6.3 ± 0.8
in rabbits fed 2% cholesterol-enriched diet plus 3 mg/day
caffeine; these differences were not statistically significant.
To investigate potential mechanisms by which caffeine
protects against high cholesterol diet-induced disruption
of BBB, we examined whether caffeine affects plasma cho-
lesterol levels. We found that rabbits fed a cholesterol-
enriched diet for 12 weeks exhibited a 10-fold increase in
total plasma cholesterol concentration from 64 ± 7 mg/dl
in controls (n = 6) to 644 ± 106 mg/dl in cholesterol-fed
rabbits (n = 6). Caffeine did not affect significantly plasma
cholesterol levels in rabbits fed control diet or cholesterol-
enriched diet; values were 87 ± 12 mg/dl for control diet
plus 3 mg/day caffeine animals and 593 ± 278 for choles-
terol-enriched diet plus 3 mg/day caffeine animals.
Caffeine blocks high cholesterol diet-induced extravasation of fibrinogen Figure 2
Caffeine blocks high cholesterol diet-induced extravasation of fibrinogen. (A) Cholesterol-enriched diet increased 
extravasation of fibrinogen in olfactory bulb and this effect was blocked by caffeine at the dose of 3 mg/day. Caffeine alone had 
no effect on extravasation of fibrinogen in normal rabbit brain. Representative images taken from 2 rabbits in each group with 
6 sections from each animal are shown. Bar = 50 µm. (B) Cholesterol-enriched diet significantly increased accumulation of 
fibrinogen in olfactory bulb and this effect was blocked by caffeine at the dose of 3 mg/day. (C) Neither cholesterol-enriched 
diet nor caffeine changed significantly plasma levels of fibrinogen. n = 4, *p < 0.05.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
Page 6 of 14
(page number not for citation purposes)
Plasma levels of high-density lipoproteins (HDL)
decreased from 34 ± 4 mg/dl in controls to 14 ± 2 mg/dl
in cholesterol-fed rabbits, and these levels were not
affected significantly by caffeine; values were 40 ± 6 mg/dl
in rabbits fed control diet plus 3 mg caffeine and 11 ± 3
mg/dl in rabbits fed cholesterol-enriched diet plus 3 mg
caffeine.
Caffeine blocks high cholesterol diet-induced increases in 
astrocyte activation and microglia density at the sites of 
BBB leakage
We examined the extent to which high cholesterol diet-
induced increases in BBB leakage was associated with ang-
iogenesis. Accordingly, sections of olfactory bulb were
stained for the endothelial markers, protein platelet
endothelial cell adhesion molecule-1 (CD31) and von
Willebrand factor; no vascularization changes were noted
in rabbits fed cholesterol-enriched diet and caffeine did
not affect vascularization patterns in control or choles-
terol-enriched diet fed animals (data not shown).
BBB disruption and high dietary cholesterol have been
shown to induce activate astrocytes and microglia [27-29].
Thus, we examined the involvement of astrocytes and
microglia in our cholesterol-fed rabbit model. Activation
of astrocytes was evaluated by immunostaining and
immunoblotting for expression levels of the astrocyte
marker glial fibrillary acidic protein (GFAP). We did not
observe any overall changes in GFAP immunostaining
and GFAP protein levels in olfactory bulb from rabbits fed
cholesterol-enriched diet in the presence or absence of caf-
feine (data not shown). However, we did observe, in 2 of
6 rabbits examined from each group and in 6 sections
from each animal, reactive astrocytes at the sites where
extravasation of IgG was present (Fig 7), and these were
not detected in rabbits fed control diet or in caffeine-
treated animals. Using lectin staining as a measure of
microglial density [27,30], we found, in 2 of 6 rabbits
examined from each group and in 6 sections from each
animal, that the cholesterol-enriched diet increased mark-
edly the numbers of micrglia, and this effect was blocked
by caffeine at the dose of 3 mg/day for 12 weeks (Fig 8).
We also demonstrated that increased microglia in olfac-
tory bulb from cholesterol-fed rabbits co-distributed with
immunopositive staining of IgG perivascularly (Fig 8).
Discussion
Here, we report that chronic ingestion of caffeine protects
against disruption of the BBB, an early event in both acute
and chronic neurodegenerative diseases [11,12]. We
found that caffeine blocked high cholesterol diet-induced
increased BBB leakage, decreased expression of endothe-
lial cell tight junction proteins, increased activation of
astrocytes, and increased microglia density in rabbit brain.
The BBB limits the entry of blood-borne pathogens, sub-
stances, drugs, and cells into brain parenchyma, and once
disrupted can compromise synaptic and neuronal func-
tion [2,31,32]. One of the common features of neurolog-
ical disorders such as stroke and Alzheimer's disease is
BBB breakdown, and BBB disruption has been shown to
precede neuronal damage in stroke [11] and Alzheimer's
disease [12]. Thus, BBB breakdown might underlie these
neurological disorders. Elevated levels of cholesterol have
emerged as a risk factor for both stroke [33] and Alzhe-
imer's disease [34] and others and we have shown that
cholesterol-enriched diets induce pathological features of
Alzheimer's disease such as learning deficit, increased Aβ
Caffeine blocks high cholesterol diet-induced leakage of  Evan's blue dye Figure 3
Caffeine blocks high cholesterol diet-induced leakage 
of Evan's blue dye. Cholesterol-enriched diet significantly 
increased leakage of Evan's blue dye in olfactory bulb (A), 
cerebral cortex (B) and hippocampus (C), and these effects 
were blocked by caffeine at the dose of 3 mg/day. n = 2, *p < 
0.05.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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plaque formation, hyperphosphorylation of tau, and neu-
ronal cell death [10,25,35-37]. Cholesterol-enriched diet
has also been shown to disrupt BBB [9,10]. Thus, choles-
terol-enriched diets might contribute to the pathogenesis
of Alzheimer's disease by virtue of its ability to compro-
mise BBB integrity. Consistent with the above findings,
the present study demonstrated that a cholesterol-
enriched diet increased the leakage of the BBB as well as
disrupted the integrity of the BBB in part by decreasing the
expression of tight junction proteins.
Caffeine blocks high cholesterol diet-induced down-regulation of tight junction proteins Figure 4
Caffeine blocks high cholesterol diet-induced down-regulation of tight junction proteins. (A) Schematic draft of a 
section of olfactory bulb, the green square indicated where the fluorescent images were taken for measures of the expression 
of occludin and ZO-1. (B) Decreased occludin immunostaining was observed in olfactory bulb from cholesterol-fed rabbits and 
this effect was blocked by caffeine. Caffeine alone had no effect on occludin immunostaining in normal rabbit brain. Represent-
ative images taken from 2 rabbits in each group with 6 sections from each animal are shown. Bar = 100 µm. (C) Quantitative 
data from B shows that high cholesterol diet significantly decreased occludin immunopositive staining in olfactory bulb, and this 
effect is blocked by caffeine. (D) Cholesterol-enriched diet decreased significantly protein levels of occludin, and these effects 
were blocked by caffeine at the dose of 3 mg/day. Caffeine alone did not significantly change protein levels of occludin in nor-
mal rabbit olfactory bulb (n = 4, *p < 0.05). (E) Decreased ZO-1 immunostaining was observed in olfactory bulb from choles-
terol-fed rabbits and this effect was blocked by caffeine. Caffeine alone had no effect on ZO-1 immunostaining in normal rabbit 
brain. Representative images taken from 2 rabbits in each group with 6 sections from each animal are shown. Bar = 100 µm. (F) 
Quantitative data from E shows that high cholesterol diet significantly decreased ZO-1 immunopositive staining in olfactory 
bulb, and this effect is blocked by caffeine. (G) Cholesterol-enriched diet decreased significantly protein levels of ZO-1, and 
these effects were blocked by caffeine at the dose of 3 mg/day. Caffeine alone did not significantly change protein levels of ZO-
1 in normal rabbit olfactory bulb. n = 4, *p < 0.05.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
Page 8 of 14
(page number not for citation purposes)
Neurological disorders, such as stroke and Alzheimer's
disease, take a huge toll on the elderly, but therapeutic
interventions for these disorders are limited. Data from
recent studies indicate that caffeine, the most commonly
ingested psychoactive drug in the world, is protective
against a number of acute and chronic neurological disor-
ders including stroke and Alzheimer's disease [13-20].
However, little is known about the mechanisms whereby
caffeine exerts its neuroprotective effects. Here, we
showed, for the first time, that chronic ingestion of caf-
feine protects against disruption of BBB. The dose of caf-
feine (3 mg/day) used in this study for 3 to 4 kg rabbits is
equivalent to an adult human weighing 70–80 kg con-
suming a single cup of coffee and is far less than the aver-
Double immunostaining of IgG extravasation and the expression of occludin Figure 5
Double immunostaining of IgG extravasation and the expression of occludin. Cholesterol-enriched diet markedly 
decreased the immunopositive staining of occludin (green) at the sites where IgG extravasation (red) was present. These 
effects were blocked by chronic ingestion of caffeine. Representative images taken from 2 rabbits in each group with 6 sections 
from each animal are shown. Bar = 20 µm.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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age caffeine consumption in the USA and Canada that is
about 200 mg per person per day [38]. Furthermore,
although the data were not included here we have evi-
dence that a ten-fold higher dose of caffeine (30 mg/day)
produces results virtually identical to the findings
reported here. Both endogenous (IgG and fibrinogen) and
exogenous (Evan's blue dye) markers were used to evalu-
ate the effects of cholesterol-enriched diet in the absence
and presence of caffeine on BBB leakage, and we found
that caffeine blocked increased BBB leakage caused by the
cholesterol-enriched diet. Furthermore, we demonstrated
that caffeine blocked high cholesterol diet-induced down-
regulation of the tight junction proteins, occludin and
ZO-1, especially where BBB leakage were apparent. Our
Double immunostaining of IgG extravasation and the expression of ZO-1 Figure 6
Double immunostaining of IgG extravasation and the expression of ZO-1. Cholesterol-enriched diet markedly 
decreased the immunopositive staining of ZO-1 (green) at the sites where IgG extravasation (red) was present. These effects 
were blocked by chronic ingestion of caffeine. Representative images taken from 2 rabbits in each group with 6 sections from 
each animal are shown. Bar = 20 µm.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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findings suggest that caffeine protects against BBB break-
down by keeping the expression levels of tight junction
proteins from decreasing in this model. Since BBB disrup-
tion can compromise synaptic and neuronal function, our
observation that caffeine protects against BBB disruption
is consistent with the findings that caffeine intake protects
against memory loss in aging and in Alzheimer's disease
[19,20].
Similar to most other brain regions, the BBB in olfactory
bulbs is normally intact and we could find no literature
suggesting that the BBB in olfactory bulbs is 'leaky' under
Double immunostaining of IgG extravasation and the expression of GFAP Figure 7
Double immunostaining of IgG extravasation and the expression of GFAP. Cholesterol-enriched diet markedly 
enhanced the immunopositive staining of GFAP (green) around the sites where IgG extravasation (red) was present. These 
effects were blocked by caffeine at the dose of 3 mg/day. Representative images taken from 2 rabbits in each group with 6 sec-
tions from each animal are shown. Bar = 20 µm.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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Double staining of IgG extravasation and microglia Figure 8
Double staining of IgG extravasation and microglia. (A) In addition to microglia, lectin staining also reveals blood ves-
sels. Cholesterol-enriched diet markedly increased the numbers of microglia (green, arrow heads) and IgG extravasation (red). 
These effects were blocked by caffeine at the dose of 3 mg/day for 12 weeks. Representative images taken from 2 rabbits in 
each group with 6 sections from each animal are shown. Bar = 50 µm. (B) In a magnified view of the white boxes as shown in 
panel A, increased microglia (arrow heads) are co-distributed with perivascular immunopositive IgG staining (arrows) in olfac-
tory bulb from cholesterol-fed rabbits. Bar = 20 µm.Journal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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normal conditions. Based on our observations from our
IgG and fibrinogen extravasation study, the BBB is indeed
intact in olfactory bulbs from rabbits fed a control diet in
the absence or presence of caffeine. Moreover, results
from our Evan's blue dye leakage assay showed that rab-
bits fed control diet in the absence or presence of caffeine
have similarly restrictive blood brain barriers in olfactory
bulb, cerebral cortex and hippocampus. Our observation
that caffeine blocks cholesterol-enriched diet induced
Evan's blue dye leakage not only in olfactory bulb but also
in cerebral cortex and hippocampus suggests that the
effects of caffeine and cholesterol-enriched diet on BBB
are general and not brain region specific.
Olfactory bulb was selected for these studies in part
because olfactory dysfunction is one of the earliest symp-
toms experienced by patients living with Alzheimer's dis-
ease and olfaction tests have been investigated as an early
diagnostic test [23,39-44]. Dysfunctions in olfaction are
not limited to perceptual impairments and changes in
olfactory thresholds, and beta amyloid plaque and tau
pathology in the olfactory system have been reported in
Alzheimer's disease [24]. Indeed, olfactory regions of
brain including olfactory bulbs have some of the highest
levels of neurofibrillary tangles and amyloid plaques in
Alzheimer's disease [45,46]. It is relevant and potentially
important that BBB dysfunctions were noted in olfactory
bulbs (as well as hippocampus and cerebral cortex) in our
model of Alzheimer's disease and that caffeine protected
against these deleterious effects. We are not aware of any
studies examining possible effects of caffeine on olfaction
perception or thresholds.
Our observations that caffeine had no effects on plasma
levels of total cholesterol and HDL indicate that caffeine
protects against high cholesterol diet-induced disruption
of BBB downstream of cholesterol. Angiogenesis and
inflammation are major factors that could lead to BBB dis-
ruption [47,48]. The observations that neither choles-
terol-enriched diet nor caffeine affect brain
vascularization indicates that angiogenesis is not likely to
play a major role in regulating BBB integrity in our animal
model. BBB disruption induces astrocytes and microglia
activation [29]. Therefore we examined the involvement
of astrocyte and microglia in our animal model. We
observed, in olfactory bulb from cholesterol-fed rabbits,
site-specific astrogliosis where BBB leakage was apparent.
In contract, astrogliosis was not observed in rabbits fed
control diet or in caffeine-treated animals. We also found
that the cholesterol-enriched diet increased the numbers
of microglia, that the increased presence of microglia co-
distributed with perivascular IgG, and that caffeine
blocked these effects. These observations are consistent
with previous reports that high dietary cholesterol induces
activation of astrocyte and microglia [27,28,30]. Although
the sequence of these events was not explored in the
present study, our observation that activation of astrocytes
and increase in the density of microglia occurred at sites
where BBB leakage was apparent prompts us to speculate
that cholesterol-enriched diet disrupts the BBB first and
that the subsequent activation of astrocytes and increases
in microglia density might be part of a potentially protec-
tive response. Most importantly, our studies demon-
strated that caffeine is protective against high cholesterol
diet-induced increases in BBB disruption, increases in
astrocytes activation, and increases in microglia density.
The protective effects of caffeine against high cholesterol
diet-induced increases in BBB disruption might happen at
the BBB per se, and the protective effects of caffeine against
high cholesterol diet-induced increases in the density of
astrocytes and microglia could be an indirect consequence
of its protective effects against BBB disruption. On the
other hand, it has been shown that caffeine (and adenos-
ine) can regulate neuroinflammation in in vitro models
devoid of BBB [49-51]. Therefore, the protective effects of
caffeine against high cholesterol diet induced increases in
astrocyte activation and increases in density of microglia
might parallel its protective effects against BBB disruption.
In the present study, detailed molecular mechanisms
whereby caffeine protects against BBB disruption were not
explored. But, we did measure plasma concentrations of
caffeine. Plasma caffeine concentrations were in the range
of 5 to 6 µM in rabbits that ingested caffeine at the dose of
3 mg/day. The method used in our study to quantify
plasma caffeine levels, however, excluded protein-bound
caffeine. The protein-bound caffeine has been shown to
be about 35% of total caffeine levels in plasma [52].
Therefore, the total plasma caffeine concentrations might
have been about 10 µM in our rabbit model. At this con-
centration, the only known targets of caffeine are adenos-
ine receptors [38]. Thus, the most likely pharmacological
effects whereby caffeine might be exerting its protective
effects against BBB disruption are blocking adenosine
receptors.
Conclusion
We conclude that chronic ingestion of caffeine protects
against high cholesterol diet-induced disruption of the
BBB. BBB is essential for brain homeostasis and, once dis-
rupted, can contribute to a variety of neurological disor-
ders. Therefore, our findings that caffeine, a safe and
readily available drug, can stabilize BBB have important
implications for therapeutic interventions against neuro-
logical disorders. Furthermore, it might be important to
control ingestion of caffeine and drugs similar to caffeine
in patients enrolled in clinical trials and/or prescribed
therapeutic strategies where selective opening of the BBB
to facilitate drug entry into brain is desired. Further
detailed studies are now warranted to determine detailedJournal of Neuroinflammation 2008, 5:12 http://www.jneuroinflammation.com/content/5/1/12
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mechanism(s) by which caffeine protects against BBB dis-
ruption, whether these effects on BBB are species-specific,
and whether pathophysiological factors in addition to
high dietary cholesterol that are related to acute and
chronic neurodegenerative diseases are implicated.
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